MedTrace Logo

Clinical Research on Comprehensive Treatment of Tuberculosis With Malignant Solid Tumor

NCT03551795 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2022-05-09

No results posted yet for this study

Summary

Invariant Natural killer T (iNKT) cells are a unique subset of lymphocytes that express homogeneous TCR recognizing KRN7000 which was up-regulated by many kinds of cancer cells.The hypothesis of the investigators is that immunotherapy strategy of infusion of iNKT cells may resist inflection and decrease the tumor burden and improve overall survival. The purpose of this study is to assess the safety and efficacy of treatment of tuberculosis with malignant solid tumor by infusing of iNKT cells.

Conditions

  • Malignant Solid Tumor

Interventions

BIOLOGICAL

Infusion of iNKT cells

The eligible patients receive twice infusions of iNKT cells(1E8\~1E10) in one course of treatment.

Sponsors & Collaborators

  • Xiaoyan Zhang

    lead OTHER_GOV

Principal Investigators

  • Qing J Xu, Ph.D · Shanghai Public Health Clinical Center, Fudan University, 2901 Caolang Road, Jin Shan, Shanghai 201508, P.R. China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2021-12-30
Completion
2022-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03551795 on ClinicalTrials.gov